Supplementary Material

# Supplementary Tables

*Tab. 1 suppl.: Most frequent tumor entities presented at the CCC from 01/2014 -10/2020*

|  |  |
| --- | --- |
| **Tumor entity** | **N (%)** |
| **Rectum** | 2515 (15.7) |
| **Colon** | 2294 (14.3) |
| **Pancreas** | 2090 (13.1) |
| **Liver (HCC and intrahepatic bile duct)** | 1855 (11.6) |
| **Stomach (incl. oesophagogastric junction)** | 1713 (10.7) |
| **Esophagus** | 1451 (9.1) |
| **Biliary tract (gall bladder, extrahepatic bile duct, ampulla vateri)** | 726 (4.5) |
| **Carcinoma of unknown primary (CUP)** | 635 (4.0) |
| **Small Bowel** | 332 (2.1) |
| **Endocrine organs** | 243 (1.5) |
| **Others** | 2141 (13.4) |
| **Total** | 15995 (100) |

*Tab. 2 suppl:* *Average change in tumor board presentation rate per treatment intention and year 2014 – 2020 and 01-10/2019 (pre-COVID-19 pandemic) versus 01-10/2020* (during COVID-19-pandemic)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Treatment intention** | **Average change/year 2014 – 2020****(%, [95 % CI)])\*** | **01-10/2019****N** **(% within 2019)** | **01-10/2020****N** **(% within 2020)** | **Change 2020 vs. 2019****N (% change of 2019, [95 % CI])** |
| **curative** | + 3.9% [1.7; 6.1] | 1171 (53.2) | 1088 (51.0) | - 83 (- 7.1%, [- 14.4; 0.9]) |
| **palliative** | + 4.4% [2.2; 6.7] | 660 (30.0) | 661 (31.0) | + 1 (+ 0.2%, [- 10.1; 11.6]) |
| **Not yet decided** | + 10.6% [5.8;15.6] | 370 (16.8) | 386 (18.1) | + 16 (+ 4.3%, [- 9.5; 20.3]) |
| **Total** | ­- | 2201(100) | 2135 (100) | - 66 (- 3.0% [- 8.6; 3.0]) |

*\* =time series analysis with a linear trend*

*Tab. 3 Suppl: Average change in tumor board presentation rate per tumor entity and treatment intention 01-10/2019 (pre-COVID-19 pandemic) versus 01-10/2020 (during COVID-19 pandemic)*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Tumor entity** | **Treatment intention** | **01-10/2019****N (% within 2019)** | **01-10/2020****N (% within 2020)** | ***Change 2020* vs*. 2019******N (%, [95 % CI]*)** |
| **Biliary tract (gall bladder, extrahepatic bile duct, ampulla vateri)** | CurativePalliativeNot yet decidedTotal | 52 (47.7)43 (39.4)15 (13.6)110 (100) | 49 (53.3)29 (31.5)14 (15.2)92 (100) | - 3 (- 5.8%, [-36.1; 39.0])- 14 (- 32.6%, [- 35.9; 11.4]) 0 (0)- 17 (- 15.6%, [- 57.5; 8.2]) |
| **Esophagus** | CurativePalliativeNot yet decidedTotal | 145 (66.0)48 (21.8)27 (12.3)220 (100) | 108 (55.7)47 (24.2)39 (20.1)194 (100) | - 37 (- 25.5%, [- 41.8; - 4.4])- 1 (- 2.1%, [- 34.4; 46.1])+ 12 (+ 44.4%, [- 11.7; 133.7])- 26 (- 11.8%, [- 27.3; 7.0]) |
| **Colon** | CurativePalliativeNot yet decidedTotal | 206 (61.1)65 (19.3)66 (19.6)337 (100) | 170 (55.7)68 (22.3)67 (22.0)305 (100) | - 36 (- 17.5%, [- 32.6; 1.1])- 3 (- 4.6%, [- 25.5; 46.7])- 1 (- 1.5%, [- 27.7; 42.4])- 32 (- 9.5%, [- 22.5; 5.7]) |
| **Pancreas** | CurativePalliativeNot yet decidedTotal | 142 (43.4)136 (41.6)49 (15.0)327 (100) | 136 (45.3)110 (36.6)52 (17.3)300 (100) | - 6 (- 4.2%, [- 24.3; 21.1])- 26 (- 19.1%, [- 37; 4])- 3 (- 6.1%, [- 28.1; 56.4])- 27 (- 8.3%, [- 21.5; 7.3]) |
| **Rectum** | CurativePalliativeNot yet decidedTotal | 252 (67.6)62 (16.6)59 (15.8)373 (100) | 225 (63.0)72 (20.2)60 (16.8)357 (100) | - 27 (- 10.7%, [- 25.4; 6.9])+ 10 (+ 16.1%, [- 17.3; 62.7])+ 1 (+ 1.7%, [- 28.9; 45.4])- 16 (- 4.3%, [- 17.2; 10.7]) |

*Tab. 4 suppl: Average change in tumor board presentation rate per tumor stage 2014 – 2020 and 01-10/2019 (pre-COVID-19 pandemic) versus 01-10/2020 (during COVID-19 pandemic)*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Tumor stage** | ***Average change/year 2014 – 2020******(%,*** [***95 % CI)***])***\**** | **01-10/2019****N (% within 2019)** | **01-10/2020****N (% within 2020)** | ***Change 2020* vs*. 2019******N (%, [95 % CI]*)*)*** |
| **Primary tumor** | + 6.2% [2.6; 10.1] | 1024 (45.9) | 1004 (46.5) | - 20 (-2.0%, [- 10.1; 7.0]) |
| **Local recurrent tumor** | + 10.4% [3.7; 17.5] | 171 (7.7) | 158 (7.3) | - 13 (-7.6%, [- 25.5; 14.7]) |
| **Metastases** |  + 4,7% [1.5; 8.1] | 1037 (46.5) | 998 (46.2) | - 39 (-3.8%, [- 11.8; 5.0]) |
| **Total** | - | 2232 (100) | 2160 (100) | - 72 (- 3.2%, [- 8.8; 2.7]) |

*\* =time series analysis with a linear trend*

*Tab. 5 suppl.:  Average change in tumor board presentation rate per tumor entity and tumor stage 01-10/2019 (pre-COVID-19 pandemic) versus 01-10/2020 (during COVID-19 pandemic)*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Tumor entity** | **Tumor stage** | **01-10/2019****N (% within 2019)** | **01-10/2020****N (% within 2020)** | ***Change 2020* vs*. 2019******N (%, [95 % CI])*** |
| **Biliary tract (gall bladder, extrahepatic bile duct, ampulla vateri)** | Primary tumorLocal recurrent tumorMetastasesTotal | 55 (50.0)7 (6.4)48 (43.6)110 (100) | 52 (56.5)1 (1.1)39 (42.4)92 (100) | + 3 (+ 5.5%, [- 35.1; 38.0])- 6 (- 85.7%, [- 96.5; 15.4])- 9 (- 18.7%, [- 46.5; 24.0])-18 (- 16.4%, [- 36.5; 10.3]) |
| **Esophagus** | Primary tumorLocal recurrent tumorMetastasesTotal | 117 (53.2)14 (6.4)89 (40.5)220 (100) | 101 (52.1)18 (9.3)75 (38.7)194 (100) | - 16 (- 13.7%, [- 33.8; 12.7])+ 4 (+ 28.6%, [- 35.8; 153.7])- 14 (- 15.7%, [- 37.9; 14.6])- 26 (- 11.8%, [- 27.3; 7.0]) |
| **Colon** | Primary tumorLocal recurrent tumorMetastasesTotal | 110 (32.6)10 (3.0)217 (64.4)337 (100) | 97 (31.8)15 (4.9)193 (63.3)305 (100) | - 13 (- 11.8%, [- 32.8; 15.9])+ 5 (+ 50%, [- 32.6; 223.1])- 24 (- 11.1%, [- 26.7; 8.0])- 32 (- 9.5%, [- 22.5; 5.7]) |
| **Pancreas** | Primary tumorLocal recurrent tumorMetastasesTotal | 164 (50.2)11 (3.4)152 (46.5)327 (100) | 158 (52.7)12 (4.0)130 (43.3)300 (100) | - 6 (- 3.7%, [- 22.5; 19.8])+ 1(+ 9.1%, [- 51.2; 142.1])- 22 (- 14.5%, [- 32.3; 8.1])- 27 (- 8.3%, [- 21.5; 7.3]) |
| **Rectum** | Primary tumorLocal recurrent tumorMetastasesTotal | 117 (31.3)38 (10.2)219 (58.6)374 (100) | 103 (28.8)34 (9.5)221 (61.7)358 (100) | - 14 (- 12.0%, [- 32.4; 14.7])-4 (- 10.5%, [- 43.4; 41.9])+ 2 (+ 0.9%, [- 16.3; 21.6])- 16 (- 4.3%, [- 17.2; 10.6]) |